A clinical trial of 699 children and adolescents (aged 10–17 years) with recent-onset type 2 diabetes has found that combined treatment with metformin and rosiglitazone is superior to treatment with metformin alone or metformin plus a lifestyle-intervention program in maintaining glycemic control. No adverse renal effects, including microalbuminuria, hypertension and renal impairment, were reported during the trial.